Carcinoma of unknown primary with gastrointestinal profile: Immunohistochemistry and survival data for this favorable subset

International Journal of Clinical Oncology

Volumn 19, Issue 3, 2014, Pages 479-484

  Varadhachary, G R ^a   Karanth, S ^a   Qiao, W ^a   Carlson, H R ^a   Raber, M N ^a   Hainsworth, J D ^b   Greco, F A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Carcinoma of unknown primary; Gastrointestinal profile; Immunohistochemistry; Molecular profiling

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; TAXANE DERIVATIVE; CDX2 PROTEIN, HUMAN; CYTOKERATIN 20; HOMEODOMAIN PROTEIN; KRT20 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCITES; BONE METASTASIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CARCINOMATOSIS; COLLOID CARCINOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; CARCINOMA; CLINICAL TRIAL; COHORT ANALYSIS; GASTROINTESTINAL TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84903268307     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0583-0     Document Type: Article

References (17)

1. Reco FA, Oien K, Erlander M et al (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23:298-304
2. Varadhachary GR (2011) Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw 12:1406-1412
3. Varadhachary GR, Raber MN, Matamoros A et al (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9:596-599 (Pubitemid 351722584)
4. Hainsworth JD, Schnabel CA, Erlander MG et al (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11(2):112-118
5. Rubin BP, Skarin AT, Pisick E et al (2001) Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev 10:77-82 (Pubitemid 32200205)
6. Barbareschi M, Murer B, Colby TV et al (2003) CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 27:141-149 (Pubitemid 36152222)
7. Park SY, Kim BH, Kim JH et al (2007) Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131:1561-1567
8. Chu PG, Chung L, Weiss LM et al (2011) Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 35(12):1830-1836
9. Roy S, Smith MA, Cieply KM et al (2012) Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diagn Pathol 7:151. doi:10.1186/1746-1596-7-151
10. Bayrak R, Haltas H, Yenidunya S (2012) The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20 ? phenotype is more specific than CDX2 antibody. Diagn Pathol 23(7):9. doi:10.1186/1746- 1596-7-9
11. Werling RW, Yaziji H, Bacchi CE et al (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27(3):303-310 (Pubitemid 36245795)
12. Dennis JL, Hvidsten TR, Wit EC et al (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766-3772 (Pubitemid 40685594)
13. Tothill RW, Kowalczyk A, Rischin D et al (2005) An expressionbased site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65:4031-4040 (Pubitemid 40775639)
14. Horlings HM, van Laar RK, Kerst JM et al (2008) Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26:4435-4441
15. Varadhachary GR, Talantov D, Raber MN et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442-4448
16. Varadhachary GR, Spector Y, Abbruzzese JL et al (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17(12):4063-4070 Epub 2011 Apr 29
17. Greco FA, Spigel DR, Yardley DA et al (2010) Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 15(5):500-506 Epub 2010 Apr 28